Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
View Patent ↗An enzymatic method is provided for treating ophthalmic disorders of the mammalian eye. Prevention of neovascularization and the increased rate of clearance from the vitreous of materials toxic to retina is accomplished by administering an amount of hyaluronidase effective to liquefy the vitreous humor of the treated eye without causing toxic damage to the eye. Liquefaction of the vitreous humor increases the rate of liquid exchange from the vitreal chamber. This increase in exchange removes those materials and conditions whose presence causes ophthalmological and retinal damage.
1. A method for inducing liquefaction of a vitreous humor to treat a disorder of a mammalian eye, said method comprising contacting with said vitreous humor of said mammalian eye an amount of hyaluronidase effective to liquefy said vitreous humor whereby said disorder is treated, wherein said hyaluronidase is defined as being free of thimerosal, and essentially devoid of hyaluronidase molecular weight fractions above 100,000, between 50,000 and 60,000, and below 20,000 as determined by 4-20% Gradient SDS PAGE electrophoresis, and wherein said hyaluronidase is defined as causing hydrolysis of the endo-N-acetyl hexosaminic bonds of hyaluronic acid.
2. The method of claim 1 , wherein said method is carried out for the purpose of treating proliferative diabetic retinopathy.
3. The method of claim 1 , where in said method is carried out for the purpose of treating age-related macular degeneration.
4. The method of claim 1 , wherein said method is carried out for the purpose of treating amblyopia.
5. The method of claim 1 , wherein said method is carried out for the purpose of treating retinitis pigmentosa.
6. The method of claim 1 , wherein said method is carried out for the purpose of treating macular holes.
7. The method of claim 1 , wherein said method is carried out for the purpose of treating macular exudates.
8. The method of claim 1 , wherein said method is carried out for the purpose of treating cystoid macular edema.
9. The method of claim 1 , wherein said hyaluronidase is in a liquid solution, and wherein the step of contacting of said enzyme with the vitreous humor comprises:
injecting said liquid solution into the vitreous humor.
10. The method of claim 1 , wherein said hyaluronidase is contacted with the vitreous humor at a dose of 5-200 International Units.
11. The method of claim 1 , wherein said hyaluronidase is contacted with the vitreous humor at a dose of 1 International Unit.
12. The method of claim 1 , wherein said hyaluronidase is administered in multiple doses.
13. The method of claim 12 , wherein a single intravitreal injection has an injectate volume of less than 100:1.
14. The method of claim 1 , wherein said hyaluronidase is prepared in a solution for injection and which has a formulation:
said hyaluronidase up to 8000 IU;
lactose at 5.0-130.0 mg; and
phosphate at 0.01-100.0 mmoles.
15. The method of claim 1 , wherein said hyaluronidase is prepared in a solution for injection and which has a formulation:
said hyaluronidase at 6500 IU;
lactose at 5.0 mg; and
phosphate at 0.02 mmoles.
16. The method of claim 1 , wherein said hyaluronidase is prepared in a solution for injection and which has a formulation:
said hyaluronidase at 500-1000 IU;
lactose at 5.0-10.0 mg; and
phosphate at 0.01-10.0 mmoles.
17. The method of claim 1 , wherein said liquefaction achieves posterior vitreal detachment (PVD).
18. The method of claim 1 , wherein the hyaluronidase is ovine testicular hyaluronidase.
19. The method of any of claims 1 - 7 , wherein prior to liquefaction said vitreous humor is free of hemorrhagic blood that permits viewing of a retina of said mammalian eye.
20. The method of any of claims 1 - 7 , wherein said contacting step is practiced in the absence of vitrectomy.